在加拿大八所学术健康中心评估儿科肿瘤中实施遗传药理学检测的障碍和促进因素。

Implementation of pharmacogenetic testing in pediatric oncology: barriers and facilitators assessment at eight Canadian academic health centres.

机构信息

Knowledge Translation Program, Li Ka Shing Knowledge Institute, Unity Health Toronto, 209 Victoria Street, Toronto, M5B 1T8, ON, Canada.

Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

出版信息

Pharmacogenomics J. 2024 Nov 19;24(6):36. doi: 10.1038/s41397-024-00356-9.

DOI:10.1038/s41397-024-00356-9

PMID:39562543

Abstract

Pharmacogenetic (PGx) testing can enhance drug safety, improve efficacy, and reduce the risk of toxicity. However, the implementation of PGx testing in Canadian pediatric oncology centers has been limited. To address this gap, the aim of this study was to assess the barriers and facilitators to implementing PGx testing for three oncology drugs in eight Canadian pediatric oncology centers and identify strategies that could be used to support PGx testing implementation. We used semi-structured interviews to identify barriers and facilitators to PGx testing and identified evidence-based strategies for PGx testing implementation through a mapping process that utilized the Theoretical Domains Framework, the Consolidated Framework for Implementation Research and the Behavior Change Wheel. We identified 38 facilitators and 26 barriers to implementation of PGx testing and mapped these to 6 implementation strategies.

摘要

药物遗传学（PGx）检测可以提高药物安全性、改善疗效并降低毒性风险。然而，PGx 检测在加拿大儿科肿瘤中心的实施受到限制。为了解决这一差距，本研究旨在评估在加拿大八个儿科肿瘤中心实施三种肿瘤药物的 PGx 检测的障碍和促进因素，并确定可用于支持 PGx 检测实施的策略。我们使用半结构化访谈来确定 PGx 检测的障碍和促进因素，并通过利用理论领域框架、实施研究综合框架和行为改变轮来确定 PGx 检测实施的循证策略。我们确定了 38 个实施 PGx 检测的促进因素和 26 个障碍，并将这些因素映射到 6 个实施策略上。